Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ConocoPhillips
COP
|
+$3.16B |
| 2 |
Merck
MRK
|
+$2.72B |
| 3 |
SLB Ltd
SLB
|
+$1.62B |
| 4 |
Target
TGT
|
+$1.6B |
| 5 |
General Mills
GIS
|
+$930M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$2.81B |
| 2 |
Blackrock
BLK
|
+$2.57B |
| 3 |
US Bancorp
USB
|
+$1.84B |
| 4 |
M&T Bank
MTB
|
+$808M |
| 5 |
Huntington Bancshares
HBAN
|
+$595M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.45% |
| 2 | Financials | 11.9% |
| 3 | Healthcare | 10.6% |
| 4 | Consumer Discretionary | 9.01% |
| 5 | Industrials | 8.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3326
Invivyd
IVVD
$179M
| $113K | ﹤0.01% |
186,680
| – | – |
|
3327
Pyxis Oncology
PYXS
$201M
| $113K | ﹤0.01% |
115,237
-14,524
| -11% | -$19.4K |
|
|
FBLA
3328
FB Bancorp
FBLA
$255M
| $113K | ﹤0.01% |
10,000
| – | – |
|
3329
Citizens
CIA
$235M
| $112K | ﹤0.01% |
24,606
| – | – |
|
|
INZY
3330
DELISTED
Inozyme Pharma
INZY
| $111K | ﹤0.01% |
122,290
-20,868
| -15% | -$28.9K |
|
|
HLVX
3331
DELISTED
HilleVax
HLVX
| $110K | ﹤0.01% |
75,937
+341
| +0.5% | +$630 |
|
|
MRDN
3332
Meridian Holdings Inc
MRDN
$178M
| $109K | ﹤0.01% |
4,608
| – | – |
|
3333
Shattuck Labs
STTK
$708M
| $108K | ﹤0.01% |
114,139
| – | – |
|
3334
Aligos Therapeutics
ALGS
$29.3M
| $105K | ﹤0.01% |
12,686
-1,600
| -11% | -$35.1K |
|
3335
MediciNova
MNOV
$65M
| $104K | ﹤0.01% |
71,506
| – | – |
|
|
SHCO
3336
DELISTED
Soho House & Co
SHCO
| $104K | ﹤0.01% |
16,810
| – | – |
|
3337
Myomo
MYO
$41.7M
| $103K | ﹤0.01% |
21,495
| – | – |
|
3338
Cibus
CBUS
$146M
| $103K | ﹤0.01% |
55,142
+13,583
| +33% | +$31.8K |
|
|
MODV
3339
DELISTED
ModivCare
MODV
| $102K | ﹤0.01% |
77,824
-34,219
| -31% | -$166K |
|
3340
Eledon Pharmaceuticals
ELDN
$269M
| $102K | ﹤0.01% |
29,987
| – | – |
|
3341
Forafric Global
AFRI
$289M
| $101K | ﹤0.01% |
11,701
-3,440
| -23% | -$32K |
|
3342
Nautilus Biotechnolgy
NAUT
$122M
| $99.4K | ﹤0.01% |
115,418
+187
| +0.2% | +$278 |
|
3343
Vuzix
VUZI
$213M
| $99.3K | ﹤0.01% |
48,683
| – | – |
|
3344
Skye Bioscience
SKYE
$20M
| $99.2K | ﹤0.01% |
62,363
| – | – |
|
|
MRSN
3345
DELISTED
Mersana Therapeutics
MRSN
| $96.6K | ﹤0.01% |
11,225
-1,280
| -10% | -$19.8K |
|
3346
DLH Holdings
DLHC
$70M
| $96.4K | ﹤0.01% |
23,811
+23
| +0.1% | +$141 |
|
3347
Western New England Bancorp
WNEB
$278M
| $96.2K | ﹤0.01% |
10,349
| – | – |
|
3348
Fractyl Health
GUTS
$112M
| $96K | ﹤0.01% |
80,664
| – | – |
|
|
AGEN
3349
Agenus
AGEN
$334M
| $95.8K | ﹤0.01% |
63,685
+15,731
| +33% | +$45.3K |
|
3350
Corvus Pharmaceuticals
CRVS
$1.17B
| $95.3K | ﹤0.01% |
29,968
| – | – |
|
Similar funds
Charles Schwab's Q1 2025 Portfolio in Review
As of Q1 2025, Charles Schwab held 3,548 positions worth $533B, down 1.7% from $542B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Trading was light in Q1 2025: portfolio turnover was 3.6%. Charles Schwab opened 55 new positions and exited 74, leaving the 3,548-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 21% of assets, down from 24% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q1 2025 buy was iShares Currency Hedged MSCI Eurozone ETF: 7,259,426 shares worth $283M.
- Charles Schwab added most to ConocoPhillips in Q1 2025, an estimated $3.16B increase.
- Charles Schwab's biggest Q1 2025 reduction was Pfizer, cutting an estimated $2.81B.
- Charles Schwab fully exited Brookfield in Q1 2025, selling an estimated $218M.
- Charles Schwab's ten largest holdings make up 20% of its $533B portfolio in Q1 2025.
- Charles Schwab opened 55 new positions and closed 74 in Q1 2025.
- Charles Schwab's portfolio value fell 1.7% quarter-over-quarter to $533B.
Based on Charles Schwab's 13F filing for Q1 2025, filed 9 May 2025.